Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4354 Analysis of gastric NENS in the Czech neuroendocrine tumour registry (2009-2024)

Introduction: Czech Neuroendocrine Tumour Registry is collecting data of NEN patients and their treatment since 2009. We have already analysed SI NENs, pancreatic and thymic NENs. Now we focused on analysis of gastric NENs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: registry, gastric neuroendocrine neoplasia,

#4348 Real-world clinicopathological features and outcome of elderly patients with thymic neuroendocrine neoplasms: A retrospective single-institution analysis

Introduction: Thymic neuroendocrine neoplasms (TNENs）are rare and heterogeneous diseases. With the aging of society, there has been an increase in the proportion of elderly patients with TNENs，however, research on these patients is limited.

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: thymic neuroendocrine tumour, aged 65 years or above, clinicopathological characteristics, survival analysis, real-world,

#4346 Efficacy and safety of surufatinib in the treatment of thymic neuroendocrine tumours: A 102-case retrospective study

Introduction: The SANET-ep study confirmed that patients with non-pancreatic NET could benefit from surufatinib treatment compared with placebo. However, there is a lack of sufficient retrospective data on surufatinib’s efficacy in treating thymic neuroendocrine tumours (TNETs).

Conference:

Presenting Author:

Authors: Jia X, Sun Z, Xu J, Huang D, Chen F,

Keywords: neuroendocrine tumour, thymic, surufatinib, treatment,

#4341 Genetic factors associated with thymic tumours in patients with MEN1: A nested case-control study in the GTE/AFCE cohort of patients with MEN1

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant syndrome due to mutations inactivating the MEN1 gene. It is characterised by the development of tumours in various endocrine tissues. One of the major difficulties in its management is its largely unpredictable course, particularly as regards to the development of thymic tumours, which prognosis remains poor.

Conference:

Presenting Author: Journé A

Authors: Journé A, Goudet P, Sow A, Daniel S, Costa A,

Keywords: thymic tumour, risk factor, Multiple endocrine neoplasia type 1,

#4324 The diagnostic and prognostic value of 68Ga-DOTANOC and 18F-FDG PET/CT for thymic carcinoids

Introduction: Thymic carcinoid (ThC) is an extremely rare type of neuroendocrine tumour. There is insufficient evidence to evaluate ThC using 68Ga-DOTANOC and 18F-FDG PET/CT.

Conference:

Presenting Author: Xu J

Authors: Xu J, Liang Y, Chen J, Song S,

Keywords: SSTR, FDG, PET/CT, thymic carcinoid,